S-1/A: Artelo Biosciences Seeks $10.9M in Offering Amid Nasdaq Delisting Threat

Artelo Biosciences, a clinical-stage biopharmaceutical company, is conducting a best-efforts public offering to raise up to $10.9 million while addressing Nasdaq listing compliance issues and reporting positive interim clinical trial data.

Summary

• Artelo Biosciences is a clinical-stage biopharmaceutical company focused on lipid-signaling modulation pathways, including the endocannabinoid system.
• The company is conducting a "best efforts" public offering of up to 1,641,587 shares of common stock or pre-funded warrants at an assumed public offering price of $7.31 per share.
• The offering aims to raise approximately $10.9 million in net proceeds, which will be used for working capital and general corporate purposes.
• Placement Agent Warrants, exercisable for 4.0% of the aggregate shares sold, will be issued at an exercise price of $9.50 per share.
• Artelo Biosciences faces a Nasdaq delisting threat due to not meeting the minimum stockholders' equity requirement of $2.5 million, with an extension granted until March 30, 2026, to regain compliance.
• A 1-for-3 reverse stock split was effective on March 10, 2026, reducing outstanding shares from 2,124,772 to approximately 736,127.
• The company recently issued 12% bridge notes totaling $350,300 in principal amount ($210,000 from Vanquish Funding Group Inc. and $100,000 from Boot Capital LLC) on March 12, 2026, convertible at a price greater of $0.125 or 75% of the lowest trading price.
• Interim results from the Phase 2a CAReS trial for ART27.13 (cancer-related anorexia) showed a mean weight gain of over 6% in the treatment group compared to a 5% loss in the placebo group, with a favorable safety profile.
• Phase 1 clinical trial for ART26.12 (chemotherapy-induced peripheral neuropathy) demonstrated favorable safety, tolerability, and dose-dependent, linear absorption.
• ART12.11, a proprietary CBD cocrystal, has U.S. patent protection until December 10, 2038, and has shown improved pharmacokinetics and efficacy in nonclinical studies.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a high-risk investment due to critical financial challenges, including a Nasdaq delisting threat and significant dilution from the current offering and recent debt, despite promising early-stage clinical trial results for its product candidates.

Positives

• Positive interim Phase 2a clinical trial results for ART27.13 in cancer-related anorexia, demonstrating a mean weight gain of 6.38% in the treatment group compared to a 5.42% loss in the placebo group, with a maximum individual gain of 18.5%.
• Favorable safety and tolerability profile observed for ART27.13 in the CAReS trial, consistent with prior Phase 1 findings, with no drug-related serious adverse events reported.
• Successful completion of Phase 1 clinical trial for ART26.12, showing good safety, tolerability, and dose-dependent, linear absorption, supporting its development for chemotherapy-induced peripheral neuropathy (CIPN).
• ART12.11, the proprietary CBD cocrystal, benefits from strong intellectual property with a U.S. composition of matter patent enforceable until December 10, 2038, and granted/validated in 21 additional countries.
• Nonclinical studies for ART12.11 have shown improved stability, solubility, bioavailability, and efficacy compared to other forms of CBD.
• Management team possesses experience in developing, commercializing, and partnering ethical pharmaceutical products.

Negatives

• The company is at risk of delisting from Nasdaq due to non-compliance with the minimum stockholders' equity requirement of $2.5 million, with a deadline of March 30, 2026, to cure the deficiency.
• New investors in this offering will experience immediate and substantial dilution of approximately $4.03 per share.
• The offering is on a "best efforts" basis, meaning there is no guarantee that the company will raise the targeted $10.9 million, potentially leaving it with insufficient capital for business plans.
• The company's historical net tangible book value was negative $(3.3) million, or $(4.92) per share, as of December 31, 2025.
• Recent issuance of 12% bridge notes totaling $350,300 in principal amount (for $310,000 cash) with potentially highly dilutive conversion terms (greater of $0.125 or 75% of the lowest trading price during the ten preceding trading days upon an Event of Default).
• There is no established public trading market for the pre-funded warrants or the Placement Agent Warrants, limiting their liquidity.

Risks

• The public offering price for the securities may not be indicative of the fair value or actual market value of the common stock.
• Management will have broad discretion over the use of proceeds from this offering, which may not be used effectively to improve financial condition or market value.
• There is no public market for the pre-funded warrants being offered, limiting their liquidity.
• Holders of pre-funded warrants will not have rights as stockholders until the warrants are exercised.
• The pre-funded warrants are speculative in nature, and there is no assurance the common stock price will exceed the exercise price.
• As a "best efforts" offering, there is no minimum amount of securities required to be sold, and the company may not raise sufficient capital for its business plans.
• Investors will experience immediate and substantial dilution from this offering, and further dilution may occur from future equity issuances or exercise of outstanding options and warrants.
• The company's common stock may be delisted from Nasdaq if it fails to comply with continued listing standards, which could depress the stock price and limit liquidity.
• Purchasers who enter into a securities purchase agreement in this offering may have rights (e.g., breach of contract claims, covenants against variable rate financings and subsequent equity sales) not available to other purchasers.
• The market price of the company's shares is subject to wide fluctuations and volatility, potentially leading to substantial losses for investors.

Future Outlook

Artelo Biosciences intends to use the net proceeds from this offering for working capital and general corporate purposes. The company plans to continue developing its product candidates, including advancing ART26.12 for chemotherapy-induced peripheral neuropathy and ART12.11 for various indications such as anxiety disorders, PTSD, depression, epilepsy, and insomnia. The company expects to make its products available via prescription after obtaining marketing authorization and plans to retain internal development and commercialization rights, while also considering collaborations to maximize stockholder value.

Management Comments

• "Our product candidate pipeline broadly leverages leading scientific methodologies and balances risk across mechanisms of action and stages of development."
• "We believe a more consistent and improved bioavailability profile may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition."
• "Our management team has experience developing, commercializing, and partnering ethical pharmaceutical products, including several first-in-class therapeutics."

Industry Context

StockSavvy.ai notes that Artelo Biosciences operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical sector, focusing on novel therapeutics targeting lipid-signaling modulation pathways. The company's pipeline addresses significant unmet medical needs, such as cancer-related anorexia (where no FDA-approved treatment exists) and chemotherapy-induced peripheral neuropathy (CIPN, also lacking approved treatments). While positive early clinical data for ART27.13 and ART26.12 are encouraging, the company's financial challenges, including Nasdaq compliance issues and the need for capital raises, are common for early-stage biotech firms. The development of a proprietary CBD cocrystal (ART12.11) positions Artelo in a growing market, but also one with increasing competition and regulatory scrutiny.

Comparison to Industry Standards

• The interim Phase 2a results for ART27.13, showing a mean weight gain of over 6% in cancer-related anorexia patients, are compelling given the lack of FDA-approved treatments in this area. This outcome compares favorably to the typical progression of cancer anorexia cachexia syndrome, which often involves significant weight loss.
• The successful completion of the Phase 1 study for ART26.12, demonstrating a wide safety margin and dose-dependent absorption, aligns with standard early-stage drug development milestones for novel small molecules targeting conditions like chemotherapy-induced peripheral neuropathy.
• The patent protection for ART12.11 until December 10, 2038, for its composition of matter, is a strong intellectual property position, which is a critical asset in the pharmaceutical industry, particularly for cannabinoid-based therapeutics where patent landscapes can be complex.
• The company's current financial position, including negative net tangible book value and Nasdaq listing compliance issues, is not uncommon for clinical-stage biopharmaceutical companies that are pre-revenue and heavily invested in R&D, but it highlights a higher risk profile compared to more established industry players.

Corporate Governance

Legal Proceedings

• The company is actively engaged in a regulatory process with Nasdaq to address its non-compliance with listing standards, including an appeal to a hearing panel and a granted extension to March 30, 2026, to cure the stockholders' equity deficiency.

Related Party Transactions

• Bevilacqua PLLC, legal counsel to the company, holds 2,691 shares of common stock and 8,071 shares of common stock issuable upon exercise of warrants.
• Gregory D. Gorgas (President, CEO, and Director) beneficially owns 32,138 shares, including shares held directly, indirectly, and issuable from options and warrants.
• Connie Matsui (Director, Chair of the Board) beneficially owns 48,702 shares, including shares held directly and issuable from options and warrants.
• Other directors and executive officers (Steven Kelly, Douglas Blayney, R. Martin Emanuele, Gregory R. Reyes, Tamara A. Favorito, Mark E. Spring) also beneficially own shares and/or options/warrants.
• The company entered into securities purchase agreements with Vanquish Funding Group Inc. and Boot Capital LLC for 12% bridge notes on March 12, 2026.
• An Equity Purchase Agreement (ELOC) was entered into with Square Gate Capital Master Fund, LLC Series 5 on January 30, 2026.

Stakeholder Impact

• Shareholders: Existing shareholders will experience significant dilution from the current offering and potential future capital raises. The risk of Nasdaq delisting poses a threat to liquidity and share price. Positive clinical trial results could provide long-term value.
• New Investors: Will face immediate and substantial dilution. Their investment is speculative, with no public market for warrants.
• Employees: Continued employment and potential for growth if product candidates succeed, but financial instability and delisting risk could create uncertainty.
• Creditors: Holders of the recently issued 12% bridge notes have specific conversion rights upon default, which could impact the company's capital structure.
• Patients: Potential for new therapeutic options for unmet medical needs like cancer-related anorexia and chemotherapy-induced peripheral neuropathy if the company's product candidates successfully complete development and gain regulatory approval.

Next Steps

• Complete the current "best efforts" public offering by March 31, 2026, to raise capital.
• Regain compliance with Nasdaq's minimum stockholders' equity requirement by March 30, 2026, to avoid delisting.
• Continue the Phase 2a CAReS clinical study for ART27.13 in cancer-related anorexia.
• Advance ART26.12 through clinical development for chemotherapy-induced peripheral neuropathy (CIPN).
• Develop ART12.11 for multiple potential indications, leveraging its patent-protected cocrystal composition.
• Potentially seek collaborations with biopharmaceutical partners to maximize stockholder value.

Key Dates

Recommendation

Artelo Biosciences presents a mixed investment profile. While the positive interim clinical data for ART27.13 and ART26.12 are encouraging and address significant unmet medical needs, the company faces critical financial challenges, including a Nasdaq delisting threat due to insufficient stockholders' equity and substantial dilution from the current 'best efforts' offering. The recent issuance of high-interest, potentially dilutive bridge notes further highlights financial strain. A seasoned investor would likely 'hold' to monitor the outcome of the Nasdaq compliance deadline and the success of the capital raise, as these near-term financial risks heavily outweigh the promising, but still early-stage, clinical developments.

Keywords

Artelo Biosciences, ARTL, biopharmaceutical, clinical stage, SEC filing, S-1/A, public offering, common stock, pre-funded warrants, placement agent warrants, Nasdaq, delisting, reverse stock split, ART27.13, cancer-related anorexia, CAReS trial, ART26.12, CIPN, FABP5 inhibitor, ART12.11, CBD cocrystal, lipid signaling, endocannabinoid system, capital raise, dilution, bridge notes